Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A user experienced hair loss and thinning after starting a high-dose vitamin B complex. They are seeking advice on whether others have had similar experiences.

Cold shock therapy may promote hair growth by stimulating follicular muscles and affecting stem cells. The exact mechanisms and full range of elements involved are not yet fully understood.

Using PP405 and Clascoterone after a hair transplant may not cause issues if the transplant didn't achieve native density, but could lead to competition for blood supply if it did. Some users suggest waiting for these drugs to be available, as they might not significantly impact blood supply or regrowth.

PP405 increased hair density by 20% in 31% of participants, but results are considered underwhelming. Minoxidil and finasteride are seen as more effective treatments.

PP405's effectiveness in increasing hair density is questioned due to a small sample size, despite investment from Google Ventures. Users express skepticism and suggest waiting for more conclusive results.

Eucapil is discussed as a potential hair loss treatment with some believing it to be effective, though its efficacy compared to finasteride is debated. It is considered an anti-androgen treatment, often used alongside other treatments like minoxidil and finasteride, but lacks independent studies to fully support its effectiveness.

Kintor Pharmaceutical's KX-826 shows promising results for hair loss treatment. Users discuss the use of anti-androgens like spironolactone and RU58841, noting concerns about concentration and safety.

Mallia Aesthetics has developed MAL-838, a hormone-free product derived from sCD83, which stimulates hair growth without disrupting the skin microbiome. sCD83 promotes hair growth by activating hair follicles and preventing cell death, offering a localized treatment without systemic side effects.

Creatine generally does not affect hair loss, but some report increased shedding due to higher DHT levels. Many manage hair loss with dutasteride, finasteride, and minoxidil.

The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

Breezula (clascoterone) is expected to be available by late 2026, showing good long-term results with minimal side effects. KX-826 (pyrilutamide) acts faster but is still in earlier development stages.

Verteporfin and BPC-157 are being discussed as potential treatments for hair loss. The conversation also mentions Minoxidil, finasteride, and RU58841.

Breezula (cb-03-01) and kx-826 are discussed as hair loss treatments. Kx-826 is available on Kintor's website, while Breezula is available on the grey market.

Pyrilutamide is a selective AR antagonist with a high binding affinity, making it effective in competing with DHT for androgen receptors. The 1% concentration is more effective than the 0.5%, but the latter may suffice for mild hair loss; the drug is considered a good option for those avoiding 5AR blockers due to side effects.

The conversation discusses the synthesis and potential use of JXL069 and PP405 for hair loss treatment, with skepticism about their effectiveness and concerns about safety. Users mention that JXL069 has shown no results in hair growth, and there is confusion about its identity and effectiveness compared to PP405.

Amino acids like lysine, methionine, and cysteine may help with androgenetic alopecia when taken in high doses along with a DHT blocker. Users discuss combining these with treatments like Minoxidil, finasteride, and RU58841.

The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.

Ritlecitinib and PP405 show promise for hair regrowth. Diagnosing the cause of hair loss is crucial before treatment.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

There is an inconsistency between the molecular weight and formula listed on EveryChem's product page and the analytical PDFs for 3HP and PP30, suggesting a possible error in the product description. Concerns are raised about EveryChem's business practices and lack of transparency in testing and manufacturing.

Finasteride reduces DHT production, so blood tests can track hormonal changes. Pyrilutamide blocks androgen receptors without altering hormone levels, making blood tests less useful for detecting its effects.

Creatine might speed up hair loss in those prone to male pattern baldness, possibly due to increased DHT levels. Some users experience no issues when using creatine with treatments like finasteride, minoxidil, or dutasteride.

Users discussed the effectiveness of Everychem's solution, similar to PP405, with some reporting improved hair thickness and new growth. Concerns were raised about safety and the legitimacy of the product, with some users advising against purchasing research chemicals.

PP405 may promote short-term hair growth by pushing follicles into the growth phase, but concerns exist about long-term effects due to lack of rest phases. Users discuss various treatments like finasteride, minoxidil, spironolactone, alfatradiol, and investigational drugs like KX-826 and GT20029 for hair maintenance and regrowth.

A woman with AGA and CTE has been taking multiple hair loss treatments including spironolactone, dutasteride, finasteride, bicalutamide, birth control, and minoxidil without success. Steroid injections, however, dramatically and immediately stopped her hair loss, though the effect lasts less than a month.

The conversation discusses the delay in the PP405 Phase 2 study results, now expected by the end of 2025, and skepticism about research practices. There is also mention of optimism for Amplifica's AMP303 and a topical treatment in early testing.

The conversation discusses hair thinning and the potential role of vitamin D deficiency in hair loss, with suggestions to take vitamin D3 supplements. The user also mentions having diffuse thinning and a slightly receding hairline.